Table 2. T2D-related metabolites selected from previous report (Lee et al., 2016).

Metabolites*	NGT vs T2D		PD vs T2D		Postprandial glucose
	OR (95% CI)	P-value	OR (95% CI)	P-value	Effect	P-value
C14:1	1.62 (1.42–1.84)	5.75E-13	1.57 (1.38-1.79)	3.99E-12	0.16	1.88E-14
C16	1.73 (1.51–1.98)	2.46E-15	1.40 (1.24–1.58)	7.68E-08	0.2	4.67E-21
Glycine	0.45 (0.39–0.52)	6.03E-27	0.69 (0.60–0.78)	1.07E-08	−0.23	1.69E-28
Creatinine	0.56 (0.48–0.65)	1.58E-13	0.77 (0.67–0.88)	1.27E-04	−0.12	5.48E-07
lysoPC a C18:2	0.49 (0.42–0.56)	1.78E-22	0.71 (0.63–0.81)	1.24E-07	−0.25	1.26E-31
PC aa C34:2	1.58 (1.39–1.81)	5.64E-12	1.31 (1.17–1.47)	4.00E-06	0.12	2.25E-08
PC ae C36:0	1.43 (1.26–1.63)	4.82E-08	1.57 (1.38–1.79)	4.02E-12	0.11	4.57E-07
PC ae C36:2	0.64 (0.56–0.73)	5.07E-11	0.77 (0.68–0.87)	3.80E-05	−0.14	3.43E-11
Hexose	6.75 (5.43–8.40)	9.14E-66	4.11 (3.41–4.95)	1.20E-49	0.46	1.19E-118

^*C14:1, tetradecenoylcarnitine; C16, hexadecanoylcarnitine; lysoPC a C18:2, lysophosphatidylcholine acyl C18:2; PC aa C34:2, phosphatidylcholine diacyl C34:2; PC ae C36:0, phosphatidylcholine acyl-alkyl C36:0; PC ae C36:2, phosphatidylcholine acyl-alkyl C36:2